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in Childhood and Adolescence
Stephanie Markovina,1 Perry W. Grigsby,1–4 Julie K Schwarz,1,2 Todd DeWees,1 Jeffrey F. Moley,2,5
Barry A. Siegel,2,3 and Stephanie M. Perkins1,2
Background:Well-differentiated thyroid carcinoma in children and adolescents is a rare disease with favorable
prognosis despite regional and distant metastasis at presentation in many patients. Treatment recommendations
are varied and there is little consensus on follow-up guidelines for these patients.
Methods: Medical records of patients less than 22 years of age treated at our institution were reviewed. One
hundred twelve patients treated between 1969 and 2009 were selected for further analysis. Effects of patient and
tumor characteristics on progression-free survival (PFS) were evaluated along with the predictive value of
whole-body 131I scintigraphy in the follow-up setting.
Results: Overall survival at 20 years and 30 years was 100% and 94.4%, respectively. PFS at 10, 20, and 30
years was 71%, 62%, and 55%, respectively. Although male patients and younger patients presented with more
advanced disease, sex, and age at diagnosis had no effect on risk of PFS. Additionally, neither the presence of
vascular invasion, capsular extension, positive margins, nor soft tissue invasion had an effect on PFS. Mean
time to recurrence in patients who underwent immediate postoperative 131I therapy was 3.8 years compared to
14.1 years in patients who either never received 131I therapy or were treated in the salvage setting ( p< 0.0001).
Negative posttreatment whole-body 131I scintigraphy was strongly predictive for decreased risk of recurrence,
especially in patients with three consecutive negative scans.
Conclusions: Pediatric patients are more likely to present with advanced disease and for this reason, the
majority of patients treated at our institution receive postoperative 131I. Long-term surveillance is required in
this population because of the risk of late recurrences. Whole-body 131I scintigraphy is useful for risk strati-
fication; after three consecutive negative scans, the risk of recurrence is low.
Introduction
Thyroid cancer in childhood is rare, however, recentanalyses suggest that the incidence is increasing. Data
from the National Cancer Institute Surveillance, Epidemiol-
ogy, and End Results registry demonstrate an increasing in-
cidence of thyroid cancer in patients under the age of 20 (1,2).
Well-differentiated thyroid carcinoma (DTC) in children is in
many ways a distinct disease from that in adults. The risk of
mortality from thyroid cancer in this patient population is
exceedingly low. At the same time, children more often
present with extensive disease and have a higher frequency of
recurrence (3,4).
The appropriate initial management and follow-up for these
young patients who have an excellent survival but require life-
long surveillance is controversial. Surgical removal of the
thyroid is performed on nearly all patients, however, cervical
lymphadenectomy and postoperative treatment with 131I are
variably used (4–7). Posttreatment surveillance guidelines are
not standardized, although it is known that these patients are at
risk of recurrence for decades after diagnosis. Posttreatment
surveillance imaging may help further characterize risk groups
and guide individual treatment recommendations. In order to
better understand the treatment approach and prognostic fac-
tors for thyroid cancer in children and adolescents, we retro-
spectively evaluated our institutional experience with patients
diagnosed and treated for DTC before the age of 22 years.
Materials and Methods
Patients
Patients less than 22 years of age diagnosed with well-
differentiated carcinoma of the thyroid were evaluated in this
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study. Patients with papillary carcinoma and its variants in-
cluding follicular variant of papillary carcinoma, follicular
carcinoma, and Hu¨rthle cell carcinoma were included. Pa-
tients with medullary thyroid cancer were excluded. A total
of 112 patients meeting these criteria were evaluated at the
Mallinckrodt Institute of Radiology at Washington Uni-
versity School of Medicine between 1969 and 2009. Data
were obtained by review of the medical record and/or by
direct communication with the patient or parents. This ret-
rospective study was performed under a protocol approved by
the Washington University Institutional Review Board
(protocol number 201010705), with waiver of consent.
Treatment and follow-up
All patients were treated with curative intent and under-
went surgical resection. Surgical treatment was total thy-
roidectomy in 102 (91.1%), subtotal thyroidectomy in 3
(2.7%), and lobectomy in 7 (6.3%). Cervical lymphade-
nectomy was performed in 70% of patients, consisting of
excision in 49% and modified radical neck dissection in 21%.
The remaining 33 (30%) had no surgical removal of neck
lymph nodes. Postoperative 131I was administered to 92 pa-
tients (82%). The administered activity of 131I given as initial
treatment was determined based on our treatment guidelines,
which utilize the standard guidelines for adult patients in-
corporating reductions based on the weight of the child (8,9).
Our standard adult treatment recommendations included an
administered activity of 25–50mCi of 131I for patients who
have residual normal thyroid tissue remaining resulting in
minimal thyrotropin (TSH) elevation. Patients with no lymph
node involvement receive 100mCi, while lymph node-posi-
tive patients receive 150mCi. Patients with distant metastatic
disease receive 250mCi, unless the disease includes bulky or
diffuse lung involvement, in which case the dose is reduced to
50–100mCi. For children, dose adjustments are made on a
per kilogram basis using the doses described above for a
standard 70-kg person.
Administered activity of 131I ranged from 25mCi
(0.93GBq) to 270mCi (10.0GBq). 131I administrations were
repeated for patients with persistently positive posttreatment
whole-body 131I scintigraphy. At least one repeat adminis-
tration of 131I was given to 45 patients (40%). Twenty pa-
tients did not receive 131I, 47 received a single administration,
26 received two, 11 received three, 4 received four, 2 re-
ceived five, and 2 received six. For those patients treated with
131I, cumulative administered activity ranged from 25mCi
(0.93GBq) to 970mCi (35.89GBq). Posttreatment surveil-
lance consisted of physical examination and laboratory
studies, including TSH, thyroglobulin, triiodothyronine, and
free thyroxine for all patients. Beginning in the 1990s, thy-
roglobulin levels and thyroglobulin antibodies were moni-
tored for all patients.
Whole-body 131I scintigraphy was performed in 74% of
patients. Whole-body 131I scintigraphy was performed using
an 131I dosage of 70lCi/kg (with a maximum dosage of
5mCi in pediatric patients). Prior to administration, patients
were prepared either by withdrawal of replacement thyroid
hormone or, since 1997, by thyrogen administration. Thyroid
withdrawal for approximately 3 weeks was typical, after
which TSH was measured and 131I given if TSH exceeded
30 lIU/mL. Thyrogen was administered on each of 2 con-
secutive days followed by administration of 131I on the third
day. Diagnostic whole-body 131I scintigraphy was performed
48 hours after radiopharmaceutical administration using
gamma cameras fitted with high-energy collimators. Typi-
cally, both anterior and posterior whole-body scans were
performed, along with additional anterior, posterior, and both
lateral spot images of the head and neck region. It has been
our policy to perform whole-body 131I scintigraphy yearly
after thyroid ablation for the first 2 years followed by a third
scan 5 years after ablation if the prior scans showed no evi-
dence of disease.
Data on the number of negative follow-up scans for each
patient were collected. For analysis, patients were catego-
rized as having persistently positive scans, one negative scan,
two negative scans, or three or more negative scans. Disease
recurrence was defined as new site(s) of disease on whole-
body 131I scintigraphy after any number of negative 131I scans
or pathologically proven recurrence in subjects where the
presence of disease was suggested on physical examination.
Additionally, an elevated thyroglobulin level was designated
as disease recurrence, at which time further imaging, in-
cluding whole-body 131I scintigraphy, ultrasonography,
or 18F-fluorodeoxyglucose positron emission tomography
(FDG-PET) were performed to determine the site of recur-
rence. For patients with persistently positive whole-body 131I
scintigraphy, progression was defined as new recurrent dis-
ease on physical examination or new areas of uptake on 131I
scintigraphy.
Variables
Information regarding margin status, vascular invasion,
capsular involvement, and soft tissue invasion were avail-
able for all but one patient. Extent of disease at presentation
was known for all patients and was recorded as disease
confined to the thyroid, involvement of the cervical lymph
nodes, or pulmonary metastatic disease. Additionally, the
number of consecutive negative whole-body 131I scans
was evaluated with respect to risk of recurrence. Variables
analyzed for effect on progression-free survival (PFS) in-
cluded age at diagnosis, sex, race/ethnicity, tumor exten-
sion, vascular invasion, extent of disease, extent of surgery,
and treatment with 131I. PFS curves were generated using
the Kaplan-Meier method with statistical significance as-
sessed by the log-rank method. v2 analysis was used for
comparison of age groups. t Tests were used for comparison
of data with continuous variables, while v2 tests were used
for dichotomous data.
Results
Patient and tumor characteristics
Patient and tumor characteristics are shown in Table 1.
Age at diagnosis ranged from 4.2 to 21.9 years with a median
of 17.7 years. All patients had a minimum of 5 years of
follow-up (median follow-up, 18.1 years; range, 5.0–42.8).
All but four patients had either lymph node involvement or
tumor size greater than 1.0 cm. Pathologic findings included
thyroid capsular invasion in 61%, vascular invasion in 39%,
soft tissue invasion in 30%, positive margins in 31%, and
bilateral thyroid involvement in 31%. Overall, 35% of pa-
tients presented with disease confined to the thyroid, 55% had
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disease involving the cervical lymph nodes, and 10% had
pulmonary metastatic disease. Male patients were more
likely to present with metastatic disease to the lungs (21.7%
versus 6.7%, p = 0.031).
Recurrence Characteristics and Salvage Therapy
Overall survival at 20 years and 30 years was 100% and
was 94.4%, respectively, with only 1 death in the cohort (Fig.
1). One patient died of congenital heart disease 37 years after
diagnosis. At the time of last follow-up, 117 patients were
alive with no evidence of disease and 4 patients were alive
with persistent thyroid carcinoma. Median age at last follow-
up was 34.7 years (range, 11.9–63.5 years). Forty patients
(36%) have experienced recurrent disease. Patterns of failure
consisted of recurrence in the thyroid bed alone in 7, in cer-
vical lymph nodes in 24, and pulmonary metastatic disease in
6. Of the 40 patients who experienced recurrent disease,
treatment at the time of relapse was surgery in 9, surgery and
131I therapy in 15, 131I therapy alone in 15, and unknown
therapy in 1.
The time to first recurrence ranged from 8 months to 36
years (mean 8.3 years, Fig. 2). The majority of recurrences
occurred prior to 10 years. However, there was a significant
difference in time to recurrence depending on whether or not
the patient received initial 131I therapy. Mean time to recur-
rence in patients who underwent immediate postoperative
131I therapy was 3.8 years compared to 14.1 years in patients
who either never received 131I therapy or were treated in the
salvage setting ( p < 0.0001). No patients treated with 131I
failed after 20 years of follow-up, whereas 25% of the re-
currences in patients not treated with 131I failed after 20
years, with 2 recurrences after 35 years.
Prognostic factors
PFS at 10 years, 20 years, and 30 years was 72.2%, 63.0%
and 45%, respectively (Fig. 1). Although male patients and
younger patients presented with more advanced disease,
sex and age at diagnosis had no affect on risk of progres-
sion. Additionally, neither the presence of vascular invasion,
capsular extension, positive margins nor soft-tissue invasion
had an effect on PFS. Patients with tumor in both lobes of the
thyroid had worse PFS than those with unilateral disease
( p= 0.043). The recurrence rates were 22% in patients with
disease confined to the thyroid, 42% in patients with cervical
FIG. 1. Kaplan-Meier curves of overall survival and
progression-free survival for all patients (n = 113).
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FIG. 2. Time to first recurrence in years. The percentage
of patients experiencing recurrence in each time frame is on
the y-axis.
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lymph node involvement, and 46% in patients with pulmo-
nary metastases ( p = 0.103). There was a trend toward im-
proved PFS in patients with disease confined to the thyroid
but this did not reach statistical significance ( p = 0.079).
Extent of local surgery was total thyroidectomy for 90% of
the patients. We were unable to demonstrate any detriment in
PFS for patients who underwent subtotal thyroidectomy
or lobectomy. We were also unable to correlate removal of
cervical lymph nodes with risk of recurrence. For patients
treated with postoperative 131I, PFS was 70% at both 10 and
20 years of follow-up. For patients treated with surgery alone,
10- and 20-year PFS was 56.4% and 12.8%, respectively.
Tumor characteristics and outcome were also analyzed for
patients stratified by age. Comparing patients less than 16
years of age to patients between the age of 16 and 21 years of
age there was no difference in race/ethnicity or sex. However,
the younger patients were significantly less likely to have
disease confined to the thyroid gland (17.6% versus 42.3%,
p = 0.012). Lung metastases were present in 18% of patients
less than 16 years of age compared to 6% of the older patients
( p = 0.066). Additionally, younger patients were more likely
to have vascular invasion and soft tissue invasion ( p = 0.018
and 0.006, respectively). However, there was no difference in
PFS or overall survival based on age.
Follow-up whole-body 131I scintigraphy
and thyroglobulin levels
To determine the predictive value of surveillance whole-
body 131I scintigraphy in this pediatric population, we eval-
uated recurrence risk as a function of consecutive negative
scans. A total of 84 patients (75%) underwent whole-body
131I scintigraphy. Persistently positive scans occurred in 18
(21%) patients. There were 49 patients with one negative
scan or two consecutive negative scans. Within this group, 11
patients (22.4%) experienced a recurrence. Recurrence was
identified with positive whole-body 131I scintigraphy with or
without elevated thyroglobulin levels in 10 patients (91%).
No recurrences occurred in patients who had three consecu-
tive negative scans. Patients with three consecutive negative
scans experienced an improved PFS ( p = 0.048, Fig. 3).
Most recurrences were accompanied by an increase in
serum thyroglobulin. However, 11 of 52 patients (21%) tes-
ted positive for thyroglobulin antibodies, thus rendering their
thyroglobulin results unreliable. We indentified 3 patients
who achieved negative serum thyroglobulin levels in the
absence of thyroglobulin antibodies and who then developed
recurrent disease. Recurrence was detected by whole-body
131I scintigraphy in all of these patients. Additionally, 1 pa-
tient had an elevated thyroglobulin level with no evidence of
disease on whole-body 131I scintigraphy. This patient’s dis-
ease was identified by FDG-PET.
Discussion
Well-differentiated thyroid cancer is often regarded as a
distinct disease in children compared to DTC in adults. Al-
though younger patients are more likely to present with re-
gional and distant disease, overall survival is excellent as
reported in several series (1,4–6,10–12). No randomized trial
data exist to guide treatment recommendations for pediatric
patients. Nearly all patients undergo surgical removal of the
thyroid, although removal of cervical lymph nodes and use of
postoperative 131I therapy vary. Additionally, risk factors
associated with recurrence differ among published reports
and there are few data on the use of imaging studies for
predicting risk of relapse (13–16).
Patient and tumor characteristics of our cohort are similar to
those in previous studies. We find the majority of patients are
females, with male patients and younger patients presenting
with more advanced disease. Overall survival at 20 and 30
years was 100% and 94.4%, respectively. No patients died of
thyroid cancer. Previous studies, including prior data from our
institution, have demonstrated worse PFS in younger patients,
those with positive margins, and patients with more advanced
disease (5,6). Extent of disease, age, sex, and positive margins
had no significant effect on PFS. We postulate this difference
is attributable to treatment with 131I, since 97%of patients after
2000 received 131I. Patients who received postoperative 131I
experienced an improved PFS compared with patients treated
by surgery alone. However, comparison of these treatment
approaches is limited as some patients treated with surgery
alone at our institution were not evaluated at the Mallinckrodt
Institute of Radiology and were not included in analysis.
There was a noted difference in the time of recurrence based
on treatment with 131I (Fig. 2). Although patients treated with
postoperative radioactive iodine were at a decreased risk of
relapse, the risk of failure during the first 5–10 years of follow-
up was very similar between the treatment groups. The dif-
ference in risk of recurrence reflects the greater likelihood of
late relapse in patients initially treated with surgery alone.
There was only one failure after 10 years in the group of
patients treated with radioactive iodine. In contrast, 25% of the
failures in patients who did not receive initial 131I therapy
occurred after 20 years. This finding may be the result of
obtaining routine whole-body 131I scintigraphy in patients who
underwent postoperative radioactive iodine therapy. In the
patients treated with surgery alone, only one patient was fol-
lowed with whole-body 131I scintigraphy prior to recurrence.
However, 90% of patients treated with radioactive iodine un-
derwent at least one 131I scan in the follow-up setting.
Therefore, these patients were more likely to receive repeat
radioactive iodine therapy for persistent disease and more
likely to demonstrate subsequent negative 131I results, leading
to a reduced risk of recurrence decades later.
Given the risk of recurrence many years after diagnosis,
long-term follow-up and surveillance are important for these
patients. However, what constitutes appropriate and cost-
effective follow-up of these patients remains controversial.
FIG. 3. Progression-free survival stratified by number of
consecutive negative whole-body 131I scans.
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This is especially true for younger children for whom clinical
data are even more limited. Regarding our cohort, it is im-
portant to note that the majority of our patients (70%) were
over the age of 15 years. Our data suggest that patients treated
with surgery alone can experience recurrent disease at 20 and
even 30 years after initial therapy. This leads to the desire to
develop follow-up testing that can help further delineate risk of
recurrence. In conjunction with adequate suppression of TSH,
measurement of thyroglobulin levels, and physical examina-
tion, our practice includes the use of whole-body 131I scin-
tigraphy in the follow-up setting. Previous data from our
institution have shown the predictive value of whole-body 131I
scintigraphy (16). In 76 patients between the ages of 12 and 74
years, whole-body 131I scintigraphy was performed at years 1
and 2 and then every 3–5 years after primary treatment for their
disease. There was a lower predictive value for relapse-free
survival after a single negative scan compared to that after two
negative scans (91% versus 97%, p= 0.0197). In our current
pediatric cohort, patients with persistently positive scans are at
significant risk of progression. However, in patients with three
consecutive negative scans no recurrences were observed.
Our current follow-up regimen consists of yearly whole-
body 131I scintigraphy until two negative studies are obtained.
Patients are then followed by yearly physical examination
and serum thyroglobulin measurements with whole-body 131I
scintigraphy repeated in 3–5 years. Alternatively, current
recommendations suggest that patients are followed with
routine serum thyroglobulin and neck ultrasonography with
whole-body 131I scintigraphy reserved for those patients
with abnormal serum thyroglobulin levels.
Optimal duration of complete suppression of TSH for these
patients is unknown. Medical compliance, especially in ad-
olescents, can be a problem with potential to increase risk of
recurrence. However, concerns have been raised about the
long-term effects of high levels of thyroid hormone in chil-
dren because of effects on growth and learning ability (7).
Further research on the effects of subclinical hyperthyroidism
is needed.
Our data demonstrate excellent overall survival even for
those patients with recurrent disease. This is in contrast to
adult patients over the age of 45 in whom recurrence is often
associated with poor survival (17). For those patients who
developed recurrent disease, the majority were treated with
131I, with or without additional surgery. Pediatric patients
tend to present with more advanced disease and for this
reason, the majority of patients treated at our institution have
postoperative 131I therapy. Development of recurrent disease
more than 25 years after diagnosis was seen in patients
treated with surgery alone and demonstrates the importance
of long-term follow-up. Our clinical practice incorporates
serial imaging with whole-body 131I scintigraphy as we ob-
served no recurrences after three consecutive negative scans.
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